A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride

Movetis

Status and phase: Completed; Phase 1

Conditions: Constipation

Treatments: Other: Placebo; Drug: prucalopride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00488215

PRU-GBR-10

Details and patient eligibility

About

An escalating dose of prucalopride up to a maximum of 20 mg was given once daily to 32 healthy volunteers to determine safety at the maximum tolerable dose or at 20 mg.

Full description

This is a single-centre, double-blind, placebo-controlled, cross-over trial in 32 healthy volunteers with two sessions (I and II). Each session consists of a run-in day for baseline assessments, 13 treatment days and 5 additional days for assessments. Subjects will be randomized to start with either the prucalopride or placebo session.

Between the 2 sessions, there will be a washout period of 14 to 21 days, to avoid any carry-over effect.

Enrollment: 32 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Aged between 18 and 45 years, extremes included.
2. Subject has a normal weight as defined by a Quetelet Index range of 18 - 30 kg/m2, extremes included.
3. Informed consent form signed and dated, prior to screening.
4. Healthy on the basis of a pre-trial physical examination, medical history, anamnesis, electrocardiogram, 24 hour Holter monitoring and the results of blood biochemistry and haematology tests and a urinalysis carried out in 3 weeks preceding randomization.

Exclusion criteria

1. History or suspicion of alcohol, barbiturate, amphetamine or narcotic abuse.
2. Smoking more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 6 months prior to selection.
3. History of cardiac arrhythmia's, bronchospastic or cardiovascular disease (e.g. ischemic heart disease or cerebrovascular accident), diabetes mellitus, thyrotoxicosis, Parkinsonism, drug allergy.
4. Presence of prolonged QTc (Bazett) on ECG at screening (QTc > 450 msec in male subjects, QTc > 470 msec in female subjects).
5. Use of concomitant medication, except for oral contraceptives and paracetamol. All other medication must have been stopped at least 14 days before the first dose.
6. Participation in an investigational drug trial in 30 days prior to the first visit.
7. Donation of blood in the 60 days preceding the first visit.
8. Pregnancy (as confirmed by a HCG test during screening and at day 0 of each treatment session) or breast-feeding female.
9. Subjects with positive results for HIV, hepatitis B or C at screening.
10. Female subjects of childbearing potential without adequate contraceptive protection during the trial.

Trial design

32 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

Prucalopride

Treatment:

Drug: prucalopride

2

Placebo Comparator group

Description:

Placebo

Treatment:

Other: Placebo